{"id":27407,"date":"2012-09-15T15:44:41","date_gmt":"2012-09-15T19:44:41","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=27407"},"modified":"2012-09-15T17:00:57","modified_gmt":"2012-09-15T21:00:57","slug":"hardly-justify","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2012\/09\/15\/hardly-justify\/","title":{"rendered":"hardly justify…"},"content":{"rendered":"
Reading a discussion in the recent comments<\/font><\/strong><\/u><\/a>, I ran across a reference I hadn’t seen. It was a report [ACNP Task Force Report on SSRIs and Suicidal Behavior in Youth<\/font><\/strong>] published in 2006 – yet another meta-analysis of the Clinical Trials of SSRIs in adolescents, and something of a critique of Hammad’s FDA meta-analysis<\/font><\/strong><\/u><\/a> [PowerPoint<\/font><\/strong><\/u><\/a>]:<\/div>\n
\n
ACNP Task Force report on SSRIs and suicidal behavior in youth.<\/font><\/strong><\/u><\/a>
by Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, Leon AC, Meltzer HY, Ryan ND, Shaffer D, and Wagner KD.<\/sup>
Neuropsychopharmacology<\/font><\/strong>. 2006 31[3]:473-492.
[Full Text On-Line<\/font><\/strong><\/u><\/a>]<\/div>\n

<\/p>\n

Abstract<\/u><\/font><\/strong>:
This Task Force report by the American College of Neuropsychopharmacology evaluates the safety and efficacy of selective serotonin reuptake inhibitor (SSRIs) antidepressants for depressed youth under 18 years. The report was undertaken after regulatory agencies in the United States and United Kingdom raised concerns in 2003 about the possibility that treatment of depression in children and adolescents with SSRIs may increase the risk of suicidal thinking or suicide attempts.<\/sup><\/div>\n<\/blockquote>\n
The American College of Neuropsychopharmacology<\/font><\/strong><\/u><\/a> is a primo organization for neuroscientists and psychopharmacologists, publishing Neuropsychopharmacology<\/font><\/strong><\/u><\/a>.  And as long as I seem to be having a link-fest<\/em>, let me just create us a little reference library for this post:<\/div>\n
    <\/p>\n
  1. [The 1991 hearings on suicidality with Prozac]
    FDA PSYCHOPHARMACOLOGICAL DRUGS ADVISORY COMMITTEE<\/font><\/strong>     September 20, 1991<\/u><\/a><\/li>\n
  2. [The 2004 FDA Hearings that approved the Black Box warning]
    FDA HEARING:<\/font><\/strong>     September 13, 2004 Transcript<\/u><\/a> (PDF<\/u><\/a>) (Word<\/u><\/a>)
    FDA HEARING:<\/font><\/strong>     September 14, 2004 Transcript<\/u><\/a> (PDF<\/u><\/a>) (Word<\/u><\/a>)<\/li>\n
  3. [The FDA Meta-Analyses: Hammad and Kaizar]
    Hammad’s FDA meta-analysis<\/font><\/strong><\/u><\/a>
    Do antidepressants cause suicidality in children? A Bayesian meta-analysis<\/font><\/strong><\/u><\/a><\/li>\n
  4. [Bridge’s Meta-Analysis]
    Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment<\/font><\/strong><\/u><\/a> <\/li>\n
  5. [The Institute of Medicine Conference]
    CNS CLINICAL TRIAL: SUICIDALITY AND DATA COLLECTION<\/font><\/strong><\/u><\/a> <\/li>\n
  6. [ACNP Task Force]
    ACNP Task Force report on SSRIs and suicidal behavior in youth<\/font><\/strong><\/u><\/a> <\/li>\n

    <\/sup><\/ol>\n

    So, back to the Task Force report by the American College of Neuropsychopharmacology<\/font><\/strong>, the list of Task Force Members certainly had some beyond remarkable choices: the senior author on all of Robert Gibbons papers on the subject [Mann]; three authors from Keller’s Study 329 paper [Ryan, Emslie, Wagner]; an author on the Zoloft, Paxil, Prozac, and Celexa adolescent trials [Wagner]; an author of two Prozac, one Paxil, and the TADS adolescent trials [Emslie]; and a heavy smattering of other industry affiliations: <\/div>\n
      <\/p>\n
    1. \n
      J John Mann, MD<\/strong>
      Task Force Co-Chair<\/strong>
      The Paul Janssen Professor of Translational Neuroscience in Psychiatry and Radiology, Columbia University College of Physicians and Surgeons
      Chief, Department of Neuroscience,
      New York State Psychiatric Institute
      ACNP<\/div>\n
      Industry Affiliations: <\/div>\n